IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire · Oct 6, 2026
IN8bio Highlights Glioblastoma Survival Data, Eyes Autoimmune T-Cell Engager MilestoneDefense World · Sep 28, 2026
IN8bio to Present at Sidoti Small-Cap Virtual ConferenceGlobeNewsWire · Sep 22, 2026
IN8bio to Present at H.C. Wainwright 28th Annual Global Investment ConferenceGlobeNewsWire · Sep 10, 2026
IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & DevelopmentGlobeNewsWire · Sep 9, 2026IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various forms of cancer. The company's primary therapeutic asset, INB-200, is an autologous (patient-derived) gamma-delta T cell product that has been genetically engineered and is presently undergoing a Phase I clinical study for glioblastoma and other solid tumor malignancies. Additionally, INB-100, an allogeneic (donor-derived) candidate, is also in a Phase I clinical trial, aiming to treat acute leukemia patients undergoing hematopoietic stem cell transplantation.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$0.34 | -$0.25 | Beat |
| May 7, 2026 | -$0.59 | -$0.26 | Beat |
| Mar 12, 2026 | -$0.18 | -$0.26 | Miss |
| Nov 6, 2025 | -$1.20 | -$0.85 | Beat |
| Aug 7, 2025 | -$1.50 | -$1.24 | Beat |
| May 7, 2025 | -$1.80 | -$2.10 | Miss |